Literature DB >> 11061580

In vivo modulation of CYP enzymes by quinidine and rifampin.

R A Branch1, A Adedoyin, R F Frye, J W Wilson, M Romkes.   

Abstract

BACKGROUND: The metabolism of drugs and other xenobiotics is mediated by enzymes whose activities can be modulated by different compounds. The activities of these modulators have the potential to be used to optimize drug action, prevent toxicity, or identify the enzymes involved in a reaction. This approach requires that selective agents be used for specific enzymes. However, selectivity of action has been poorly characterized in vivo.
METHODS: This study investigated the effect of 3 and 28 days of treatment with quinidine (200 mg daily) and rifampin (INN, rifampicin) (600 mg daily) on the activities of four cytochrome P450 enzymes and N-acetyltransferase in 28 healthy young male volunteers divided into three groups with a cocktail of drug probes used, including caffeine, mephenytoin, debrisoquin (INN, debrisoquine), and dapsone.
RESULTS: Quinidine selectively and almost completely inhibited the activity of CYP2D6 from day 3 through day 28 without affecting any other enzymes. Rifampin showed evidence of time-dependent induction of the activities of all measured oxidative routes of metabolism but decreased the acetylation ratio in fast acetylators. The quinidine/rifampin combination resulted in selective CYP2D6 inhibition and induction of all other enzymes evaluated over this time period, suggesting that predictable complex interactions occur with the drug combination.
CONCLUSIONS: These observations illustrate the value of simultaneous assessment of the effect of modulators on the activities of multiple specific enzymes with the drug cocktail approach.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11061580     DOI: 10.1067/mcp.2000.110561

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  25 in total

1.  Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir.

Authors:  Brian J Kirby; Ann C Collier; Evan D Kharasch; Vaishali Dixit; Pankaj Desai; Dale Whittington; Kenneth E Thummel; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2011-09-19       Impact factor: 3.922

2.  Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers.

Authors:  Kerri A Schoedel; Laura E Pope; Edward M Sellers
Journal:  Clin Drug Investig       Date:  2012-03-01       Impact factor: 2.859

3.  Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine.

Authors:  Janne T Backman; Marika T Granfors; Pertti J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  2006-04-27       Impact factor: 2.953

Review 4.  Pharmacogenetics in drug regulation: promise, potential and pitfalls.

Authors:  Rashmi R Shah
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-08-29       Impact factor: 6.237

5.  Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects.

Authors:  Yifan Zhang; Dayong Si; Xiaoyan Chen; Nan Lin; Yingjie Guo; Hui Zhou; Dafang Zhong
Journal:  Br J Clin Pharmacol       Date:  2007-02-12       Impact factor: 4.335

Review 6.  Clinical Management of Pharmacokinetic Drug Interactions with Direct Oral Anticoagulants (DOACs).

Authors:  Megan C Herink; Yan F Zhuo; Craig D Williams; Thomas G DeLoughery
Journal:  Drugs       Date:  2019-10       Impact factor: 9.546

7.  Cytochrome P450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction.

Authors:  Curtis E Haas; Daniel Brazeau; Denise Cloen; Brent M Booker; Valerie Frerichs; Colleen Zaranek; Reginald F Frye; Thomas Kufel
Journal:  Eur J Clin Pharmacol       Date:  2005-07-22       Impact factor: 2.953

8.  The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.

Authors:  Evan D Kharasch; Christine Hoffer; Dale Whittington
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

Review 9.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 10.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.